Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>The CGRP antagonists offer a novel therapeutic approach in migraine. Their utility in patients with severe forms of chronic migraine is a subject of particular interest. We present outcomes of 9 months of erenumab treatment in a cohort of patients with difficult-to-control chronic migraine, all of whom had prior unsatisfactory response to onabotulinumtoxinA.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We offered erenumab to 98 patients with a prior unsatisfactory response to onabotulinumtoxinA. Eighty of 98 had trialled greater occipital nerve injections (82%), 32/98 peripheral neurostimulation (33%) and 18/98 intravenous dihydroergotamine (18%). Thirty eight of 98 (39%) met the definition of triptan overuse and 43/98 (44%) analgesic overuse. All patients met the EHF criteria for ‘resistant migraine’. Outcome measures (recorded monthly) included days with headache limiting activities of daily living (“red”), not limiting (“amber”), headache free (“green”), and requiring triptans or other analgesics. Quality of life scores - headache impact test 6 (HIT-6), patient health questionnaire 9 (PHQ-9) and pain disability index (PDI) - were also measured.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Mean number of red days improved by − 6.4 days (SE 0.67, 95%CI − 7.7 to − 5.1, <jats:italic>p</jats:italic>=0.001) at 3 months; − 6.8 days (SE 0.96, 95%CI − 8.80 to − 4.9, <jats:italic>p</jats:italic>=0.001) at 6 months and − 6.5 days (SE 0.86, 95%CI − 8.3 to − 4.8, <jats:italic>p</jats:italic>=0.001) at 9 months. Repeated measures ANOVA confirmed improvements in the number of red (<jats:italic>p</jats:italic>=0.001), green (<jats:italic>p</jats:italic>=0.001), triptan (<jats:italic>p</jats:italic>=0.001) and painkiller days (<jats:italic>p</jats:italic>=0.001) as well as scores of the HIT-6 (<jats:italic>p</jats:italic>=0.001), PHQ-9 (<jats:italic>p</jats:italic>=0.001), and PDI (<jats:italic>p</jats:italic>=0.001) across the duration of study.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>We observed improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment.</jats:p> </jats:sec>